Source Citation
Zheng SL, Roddick AJ, Aghar-Jaffar R, et al. Association between use of sodium–glucose cotransporter 2 inhibitors, glucagon-like peptide 1 agonists, and dipeptidyl peptidase 4 inhibitors with all-cause mortality in patients with type 2 diabetes: a systematic review and meta-analysis. JAMA. 2018;319:1580-91. https://pubmed.ncbi.nlm.nih.gov/29677303
Clinical Impact Ratings
GIM/FP/GP: 
Endocrinology: 
References
- 1 Neal B, Perkovic V, Mahaffey KW, et al; CANVAS Program Collaborative Group. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377:644-57. [PMID:
28605608 ] Google Scholar - 2 Vasilakou D, Karagiannis T, Athanasiadou E, et al. Sodium–glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med. 2013;159:262-74. [PMID:
24026259 ] Google Scholar - 3 Ogawa W, Sakaguchi K. Euglycemic diabetic ketoacidosis induced by SGLT2 inhibitors: possible mechanism and contributing factors [Editorial]. J Diabetes Investig. 2016;7:135-8. [PMID:
27042263 ] Google Scholar - 4 Zinman B, Wanner C, Lachin JM, et al; EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117-28. [PMID:
26378978 ] Google Scholar
Author, Article and Disclosure Information
Affiliations:
Mayo Clinic, Rochester, Minnesota, USA (A.M.E., V.M.M.)
This article was published at Annals.org on 3 July 2018.
Submit a Comment
Contributors must reveal any conflict of interest. Comments are moderated. Please see our information for authorsregarding comments on an Annals publication.
*All comments submitted after October 1, 2021 and selected for publication will be published online only.